Search Results
Your search for Shaji K. Kumar, MD matches 33 pages
Showing 1 - 33Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy
The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed significantly improved overall survival with daratumumab plus lenalidomide/dexamethasone (DRd) vs Rd in patients with previously treated...
Shaji K. Kumar, MD, Named Editor-in-Chief of The Hematologist
Shaji K. Kumar, MD, an expert in multiple myeloma and monoclonal gammopathies, has been appointed to the position of Editor-in-Chief of The Hematologist: ASH News and Reports, the official member news magazine of the American Society of Hematology (ASH). As the seventh Editor-in-Chief of the...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...
Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for...
Treatment of Relapsed Myeloma: Options Include New Drugs, Novel Combinations
The treatment paradigm for multiple myeloma continues to evolve at a rapid pace with the introduction of new drugs and the development of drug combinations, particularly the initial approach to the treatment of newly diagnosed multiple myeloma.1 One major shift in the treatment of newly diagnosed...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
Shaji K. Kumar, MD, on Multiple Myeloma: NCCN Guidelines Update
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the latest data on treating patients with multiple myeloma, including standard-of-care induction before stem cell transplant; the role of quadruplet induction; long-term results with the combination of daratumumab, lenalidomide, and...
Venetoclax Added to Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with...
Update on Multiple Myeloma: Highlights From NCCN Virtual Congress on Hematologic Malignancies
New diagnostic criteria and modern imaging techniques, a wealth of new therapeutics, and an update on current thinking as to when to treat patients with smoldering myeloma were highlighted during the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress: Hematologic Malignancies™....
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues,1 the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus...
Addition of Venetoclax to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma: BELLINI Trial
As reported in The Lancet Oncology by Shaji K. Kumar, MD, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma but was associated...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, and colleagues, the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus lenalidomide/dexamethasone (VRd) in patients with newly diagnosed...
Outcomes in Newly Diagnosed Multiple Myeloma Unimproved by Carfilzomib Triplet vs Standard Bortezomib-Based Regimen
No superior efficacy was shown with the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) in newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT), compared with the standard of care: ...
Carfilzomib Triplet Fails to Improve Outcomes vs Standard Bortezomib-Based Regimen in Newly Diagnosed Myeloma
For newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT), the triplet regimen of carfilzomib/lenalidomide/dexamethasone (KRd) failed to improve progression-free survival vs the current...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim...
Impact of Treating Facility, Provider Volume, and Patient-Sharing in the Treatment of Patients With Multiple Myeloma
A study published by Freeman et al in JNCCN—Journal of the National Comprehensive Cancer Network found that generally, providers with more experience treating multiple myeloma have better outcomes than those with more limited experience. Providers who saw the most cases were more likely to be...
Reshaping the Treatment Landscape in Refractory Multiple Myeloma
THE TREATMENT approaches for multiple myeloma, both newly diagnosed and relapsed disease, continue to undergo major transformation as new agents and combinations are being introduced.1 This change has been driven by the introduction of novel drug classes such as monoclonal antibodies, as well as...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Treatment Trial Results
Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who are ineligible for transplant (Abstract LBA2).
Emerging Options and Sequencing Therapy in Relapsed Multiple Myeloma
Advances in the treatment of multiple myeloma have led to longer progression-free survival, but the majority of patients will still relapse despite newer treatments. A number of new drugs and combinations are under study in the hope of improving outcomes. “Multiple myeloma is a complex disease...
Shaji K. Kumar, MD, on Multiple Myeloma: Treatment Update
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses emerging therapeutic options for relapsed multiple myeloma and how best to sequence treatments.
Management of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
The treatment paradigm for multiple myeloma has changed dramatically in the past decade with the availability of several efficacious agents in various drug classes. At the National Comprehensive Cancer Network® (NCCN®) 13th Annual Congress: Hematologic Malignancies™, Shaji K. Kumar, MD, Professor...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the findings of the StaMINA trial for The ASCO Post. He said the results of the largest randomized U.S....
Novel Agents on the Horizon in Lymphoma
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings. Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma Denintuzumab...
Expert Point of View: Shaji K. Kumar, MD and Sergio A. Giralt, MD
Two experts in multiple myeloma commented on the EMN02/HO95 MM trial for The ASCO Post: Shaji K. Kumar, MD, Professor of Hematology at the Mayo Clinic, Rochester; and Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York. Both...
Oral Proteasome Inhibitor May Be a Game-changer in Myeloma
An investigational oral proteasome inhibitor currently known as MLN9708 could make the treatment of multiple myeloma much more convenient and possibly less neurotoxic, according to the results of a phase I/II study of treatment-naive multiple myeloma patients presented at the 54th Annual Meeting of ...
Expert Point of View: Shaji K. Kumar, MD
Shaji K. Kumar, MD, of the Mayo Clinic in Rochester, Minnesota, commented on the findings. “Patients with myeloma are living longer, but the disease comes back in the majority. We really need new drugs, and I think the main message of this study is that clearly patients do live longer on this...
IFM 2005-02 Update Differs From CALGB 100104: Why?
The updated analysis of the Intergroupe Francophone du Myelome (IFM) 2005-02 trial in newly diagnosed multiple myeloma patients showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival, according to...
Oral Proteasome Inhibitors Advancing in Multiple Myeloma Trials
Two orally administered proteasome inhibitors—oprozomib and ixazomib—looked encouraging in multiple myeloma studies presented at the 2014 ASH Annual Meeting and Exposition. Study Details for Oprozomib Oprozomib, given as a single agent in a dose-escalation study of heavily pretreated patients,...
